Sarepta Therapeutics June 15th Short Interest Update

Sarepta Therapeutics (NASDAQ:SRPT), According to the latest information the short interest in Sarepta Therapeutics, Inc. plummeted by 4.9% or 1,054,498 shares. The final shorts are 48.3% of the total floated shares. The positions dropped from 21,454,271 shares on May 31,2016 to 20,399,773 on June 15,2016. According to the per-day average trading of 8,013,512 shares, the days to cover are 3. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.

Sarepta Therapeutics (NASDAQ:SRPT): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $17.07 and $17.00 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $18.88. The buying momentum continued till the end and the stock did not give up its gains. It closed at $18.52, notching a gain of 3.58% for the day. The total traded volume was 3,887,052 . The stock had closed at $17.88 on the previous day.

The company shares have dropped -34.28% from its 1 Year high price. On Oct 5, 2015, the shares registered one year high at $41.97 and the one year low was seen on Apr 26, 2016. The 50-Day Moving Average price is $18.45 and the 200 Day Moving Average price is recorded at $20.35.

Stocks of Sarepta Therapeutics (NASDAQ:SRPT) rallied by 6.68% during the past week but lost 12.6% on a 4-week basis. The company has outperformed the S&P 500 by 8.45% in the past week but underperformed the index by 9.96% in the last 4 weeks.

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of unique ribonucleic acid (RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company is primarily focused on advancing the development of its potentially disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates, including its lead DMD product candidate, eteplirsen, which is an antisense PMO therapeutic in Phase III clinical development for the treatment of individuals with DMD who have an error in the gene coding for dystrophin that is amenable to skipping exon 51. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.